NZ606988A - Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia - Google Patents

Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia

Info

Publication number
NZ606988A
NZ606988A NZ606988A NZ60698811A NZ606988A NZ 606988 A NZ606988 A NZ 606988A NZ 606988 A NZ606988 A NZ 606988A NZ 60698811 A NZ60698811 A NZ 60698811A NZ 606988 A NZ606988 A NZ 606988A
Authority
NZ
New Zealand
Prior art keywords
kinetosis
vertigo
vegetative
treatment
pharmaceutical compositions
Prior art date
Application number
NZ606988A
Other languages
English (en)
Inventor
Oleg Iliich Epshtein
Original Assignee
Oleg Iliich Epshtein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44899157&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ606988(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from RU2010130356/15A external-priority patent/RU2542453C2/ru
Priority claimed from RU2010130353/15A external-priority patent/RU2542445C2/ru
Priority claimed from RU2011127052/15A external-priority patent/RU2503462C2/ru
Priority claimed from RU2011127058/15A external-priority patent/RU2536232C2/ru
Application filed by Oleg Iliich Epshtein filed Critical Oleg Iliich Epshtein
Publication of NZ606988A publication Critical patent/NZ606988A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Cardiology (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
NZ606988A 2010-07-21 2011-07-15 Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia NZ606988A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
RU2010130356/15A RU2542453C2 (ru) 2010-07-21 2010-07-21 Лекарственное средство и способ лечения вегето-сосудистой дистонии, синдрома головокружения различного генеза и кинетозов
RU2010130353/15A RU2542445C2 (ru) 2010-07-21 2010-07-21 Лекарственное средство для лечения болезни альцгеймера и способ лечения болезни альцгеймера
RU2011127052/15A RU2503462C2 (ru) 2011-07-01 2011-07-01 Способ лечения головокружения различного генеза, кинетозов и вегето-сосудистой дистонии (варианты) и лекарственное средство
RU2011127058/15A RU2536232C2 (ru) 2011-07-01 2011-07-01 Лекарственное средство для лечения болезни альцгеймера и способ лечения болезни альцгеймера
PCT/IB2011/002378 WO2012010974A2 (en) 2010-07-21 2011-07-15 Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia

Publications (1)

Publication Number Publication Date
NZ606988A true NZ606988A (en) 2015-08-28

Family

ID=44899157

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ606988A NZ606988A (en) 2010-07-21 2011-07-15 Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia

Country Status (23)

Country Link
US (1) US20130058981A1 (OSRAM)
EP (1) EP2596018A2 (OSRAM)
JP (2) JP2013536174A (OSRAM)
KR (1) KR20130102542A (OSRAM)
CN (1) CN103124741A (OSRAM)
AR (1) AR082314A1 (OSRAM)
AU (1) AU2011281248B2 (OSRAM)
BR (1) BR112013001296A2 (OSRAM)
CA (1) CA2805985A1 (OSRAM)
CL (1) CL2013000201A1 (OSRAM)
DE (1) DE112011102397T5 (OSRAM)
EA (1) EA029998B1 (OSRAM)
ES (1) ES2446643R1 (OSRAM)
FR (1) FR2962910A1 (OSRAM)
GB (1) GB2496342B (OSRAM)
IL (1) IL224336A (OSRAM)
IT (1) ITTO20110630A1 (OSRAM)
MX (1) MX355371B (OSRAM)
NZ (1) NZ606988A (OSRAM)
PE (1) PE20131065A1 (OSRAM)
PH (1) PH12013500141A1 (OSRAM)
SG (2) SG10201505676RA (OSRAM)
WO (1) WO2012010974A2 (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
JP2013532182A (ja) 2010-07-15 2013-08-15 イリイチ・エプシテイン オレグ 組み合わせ医薬組成物及び神経変性疾患に関連する疾患又は状態を治療する方法
SG187037A1 (en) 2010-07-15 2013-02-28 Oleg Iliich Epshtein Pharmaceutical compositions and methods of treatment
EA030566B1 (ru) * 2010-07-15 2018-08-31 Олег Ильич ЭПШТЕЙН Способ повышения терапевтической эффективности активированной-потенцированной формы антитела к эндогенной биомолекуле и фармацевтическая композиция
KR20180127515A (ko) * 2010-07-21 2018-11-28 올레그 일리치 엡쉬테인 당뇨병 및 대사성 장애의 치료를 위한 제약학적 복합 조성물 및 방법들
JP2013533269A (ja) * 2010-07-21 2013-08-22 イリイチ・エプシテイン オレグ 組み合わせ医薬組成物及び呼吸器の疾患又は状態に関連する疾患及び状態を治療する方法
EP2596019A2 (en) 2010-07-21 2013-05-29 Oleg Iliich Epshtein A method of treating attention deficit hyperactivity disorder
FR2962912A1 (fr) * 2010-07-21 2012-01-27 Oleg Iliich Epshtein Composition pharmaceutique d'association destinee a etre utilisee dans un procede pour traiter la maladie d'alzheimer
US20130045237A1 (en) * 2010-08-06 2013-02-21 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
RU2013111961A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
RU2013111962A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311897A (en) 1979-08-28 1982-01-19 Union Carbide Corporation Plasma arc torch and nozzle assembly
RU2113230C1 (ru) 1996-04-03 1998-06-20 Ильчиков Михаил Захарович Седативное лекарственное средство "авиаморе"
US6150500A (en) * 1996-07-12 2000-11-21 Salerno; John C. Activators of endothelial nitric oxide synthase
US5849528A (en) * 1997-08-21 1998-12-15 Incyte Pharmaceuticals, Inc.. Polynucleotides encoding a human S100 protein
RU2156621C1 (ru) * 1999-03-04 2000-09-27 Эпштейн Олег Ильич Нейротропное лекарственное средство
RU2181297C2 (ru) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
US20030087250A1 (en) * 2001-03-14 2003-05-08 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
RU2201255C1 (ru) * 2001-12-26 2003-03-27 Эпштейн Олег Ильич Лекарственное средство и способ регуляции сосудистого тонуса
UA76639C2 (uk) * 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
UA76641C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування захворювань передміхурової залози
JP2006516089A (ja) * 2002-10-02 2006-06-22 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
WO2004082597A2 (en) 2003-03-14 2004-09-30 Nutrition Research, Inc. Homeopathic formulations useful for treating pain and/or inflammmation
SG187037A1 (en) * 2010-07-15 2013-02-28 Oleg Iliich Epshtein Pharmaceutical compositions and methods of treatment
JP2013532182A (ja) * 2010-07-15 2013-08-15 イリイチ・エプシテイン オレグ 組み合わせ医薬組成物及び神経変性疾患に関連する疾患又は状態を治療する方法
EA030566B1 (ru) * 2010-07-15 2018-08-31 Олег Ильич ЭПШТЕЙН Способ повышения терапевтической эффективности активированной-потенцированной формы антитела к эндогенной биомолекуле и фармацевтическая композиция
JP2013533269A (ja) * 2010-07-21 2013-08-22 イリイチ・エプシテイン オレグ 組み合わせ医薬組成物及び呼吸器の疾患又は状態に関連する疾患及び状態を治療する方法
EP2596019A2 (en) * 2010-07-21 2013-05-29 Oleg Iliich Epshtein A method of treating attention deficit hyperactivity disorder
FR2962912A1 (fr) * 2010-07-21 2012-01-27 Oleg Iliich Epshtein Composition pharmaceutique d'association destinee a etre utilisee dans un procede pour traiter la maladie d'alzheimer
KR20180127515A (ko) * 2010-07-21 2018-11-28 올레그 일리치 엡쉬테인 당뇨병 및 대사성 장애의 치료를 위한 제약학적 복합 조성물 및 방법들
US20120258146A1 (en) * 2010-07-21 2012-10-11 Oleg Iliich Epshtein Method of treating organic diseases of nervous system, pschoorganic syndrome and encephalopathy

Also Published As

Publication number Publication date
MX2013000805A (es) 2013-10-28
WO2012010974A2 (en) 2012-01-26
JP2016199571A (ja) 2016-12-01
FR2962910A1 (fr) 2012-01-27
GB2496342B (en) 2017-12-06
KR20130102542A (ko) 2013-09-17
ES2446643A2 (es) 2014-03-10
WO2012010974A8 (en) 2013-04-25
SG10201505676RA (en) 2015-08-28
ITTO20110630A1 (it) 2012-01-22
JP2013536174A (ja) 2013-09-19
SG187160A1 (en) 2013-02-28
CN103124741A (zh) 2013-05-29
BR112013001296A2 (pt) 2017-12-19
CA2805985A1 (en) 2012-01-26
CL2013000201A1 (es) 2015-01-23
DE112011102397T5 (de) 2013-05-08
PH12013500141A1 (en) 2013-03-11
IL224336A (en) 2017-06-29
AR082314A1 (es) 2012-11-28
AU2011281248B2 (en) 2017-02-02
PE20131065A1 (es) 2013-09-23
EA029998B1 (ru) 2018-06-29
EP2596018A2 (en) 2013-05-29
GB2496342A (en) 2013-05-08
WO2012010974A3 (en) 2012-04-19
MX355371B (es) 2018-04-17
AU2011281248A1 (en) 2013-03-14
US20130058981A1 (en) 2013-03-07
ES2446643R1 (es) 2015-03-06
EA201300127A1 (ru) 2013-12-30
GB201302925D0 (en) 2013-04-03

Similar Documents

Publication Publication Date Title
NZ606988A (en) Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia
MX2012011771A (es) Aptameros para beta-ngf y su uso en el tratamiento de enfermedades y trastornos mediados por beta-ngf.
MX2015002371A (es) Inhibidores bivalentes de las proteinas iap y metodos terapueticos que usan los mismos.
EA028156B9 (ru) Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов
MX360598B (es) Inhibidores de bromodominio de benzo [c] isoxazoloazepina y sus usos.
MD20140035A2 (ro) Metodă de tratament al hepatitei virale C
MX2012007684A (es) Modificacion covalente ligando dirigida de proteina.
MX338515B (es) Derivados de tetrahidroquinolina utiles como inhibidores de bromodominio.
EA201391719A1 (ru) Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
EA201200551A1 (ru) Фармацевтическая композиция, фармацевтическая дозированная форма, способы их получения и применения для лечения
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
MX2015000813A (es) Composiciones liposómicas de inhibidores de proteasoma basadas en epoxicetona.
IN2014MN01736A (OSRAM)
MX2013008850A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
PH12012500870A1 (en) Spiro-oxindole mdm2 antagonists
NZ606969A (en) A method of treating alzheimer’s disease
EA201490653A1 (ru) Производные эстра-1,3,5(10),16-тетраен-3-карбоксамида, способ их получения, содержащие их фармацевтические препараты, а также их применение для получения лекарственных средств
GB2496337A (en) Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
UA116999C2 (uk) Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить
PH12015502535A1 (en) Process for the preparation of erythrocytes loaded with one or more substances of pharmaceutical interest and so obtained erythrocytes
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
GB2497453A (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
MX357293B (es) Anticuerpos anti-cd26 y usos de los mismos.
PH12015500062A1 (en) 3-substituted estra-1,3,5(10),16-tetraene derivatives, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 15 JUL 2018 BY FREEHILLS PATENT ATTORNEYS

Effective date: 20160217

LAPS Patent lapsed